All times are listed in CEST (Central European Summer Time)

Displaying One Session

EONS session
Date
Sat, 10.09.2022
Time
16:45 - 17:45
Location
7.3.S - Strasbourg Auditorium
Chairs
  • Mary A. Tanay (London, United Kingdom)
Session Type
EONS session
EONS session

Supportive care in cancer makes excellent cancer care possible! Recent developments (MASCC)

Speakers
  • Elaine Tomlins (Southampton, United Kingdom)
Lecture Time
16:45 - 17:00
Location
7.3.S - Strasbourg Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
16:45 - 17:45
EONS session

Cognition, sleep and the daily functioning of patients with cancer: A time for multi-modal management interventions

Speakers
  • Grigorios Kotronoulas (Glasgow, United Kingdom)
Lecture Time
17:00 - 17:15
Location
7.3.S - Strasbourg Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
16:45 - 17:45
EONS session

CN61 - Patients’ experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC): Interview results

Presentation Number
CN61
Speakers
  • Lucy Matthews (Brighton, United Kingdom)
Lecture Time
17:15 - 17:25
Location
7.3.S - Strasbourg Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
16:45 - 17:45

Abstract

Background

Little is known about patients’ interactions with Supported Self-Management (SSM) for early breast cancer (EBC), or confidence in managing their care in this pathway. The PRAGMATIC study allowed us to explore these issues.

Methods

Three clinical teams in Surrey and Sussex identified EBC patients due to enter SSM. Patients completed standardised questionnaires (separately reported) +/- semi-structured telephone interviews at baseline, 3, 6, 9 and 12 months. The interviews explored how confident patients felt managing their care, accessing services, managing side effects (SEs), and lifestyle changes.

Results

32/110 patients engaged in interviews; data are available for 30/32 at all timepoints. Participants were representative of the whole group in terms of demographics and treatment received. Patients understood the main reasons for SSM were to: a) assume responsibility for their follow up (18/32; 56%) and b) save time and money for them and the hospital (16/32; 50%). Most maintained (very/somewhat) confidence over time in managing their care and SEs, but were less confident identifying BC related signs/symptoms especially if screen detected. 19 patients contacted the SSM helpline +/- their GP. 15/19 found the helpline easy to use and 6/19 were seen by a healthcare professional. The main triggers for calling were for advice on signs/symptoms and managing SEs. 5/26 (19%) patients on endocrine therapy (ET) had stopped it completely. Most (29/32) were engaged in exercise before diagnosis, and 8/10 who discontinued during treatment resumed afterwards. The COVID-19 pandemic had a negative impact on exercise and socialising. The interviews’ free text provided a plethora of rich data. Qualitative analysis produced four overarching themes: 1) expectations and experiences, 2) emotional wellbeing, 3) clinical concerns, and 4) effect of COVID-19 pandemic.

Conclusions

SSM works for most EBC patients. Clinicians could explain that the helpline is available for psychosocial as well as physical concerns. BC teams may want to review how to help screen detected patients recognise BC related signs/symptoms, how to monitor adherence to ET and offer interventions for treatment related SEs.

Clinical trial identification

ISRCTN10777283.

Legal entity responsible for the study

University of Sussex.

Funding

Surrey & Sussex Cancer Alliance.

Disclosure

All authors have declared no conflicts of interest.

Collapse
EONS session

CN58 - Mapping the measurement of lymphoma survivors’ unmet needs and quality of life outcomes: Evidence for a lymphoma-specific questionnaire

Presentation Number
CN58
Speakers
  • Vanessa Boland (Dublin, Ireland)
Lecture Time
17:25 - 17:35
Location
7.3.S - Strasbourg Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
16:45 - 17:45

Abstract

Background

A pressing issue for cancer survivorship is the availability of care and resources for survivors. The assessment of survivors’ needs has advanced efforts to improve this. Evidence relating to lymphoma-specific cancer survivors and the measurement of their needs and quality of life outcomes is limited. While various instruments assessing cancer patients' needs and quality of life are available, finding the most relevant, lymphoma-specific and psychometrically rigorous instruments is needed to ensure that future care is responsive to survivors’ needs. Therefore, this research aimed to conduct an instrument development process and a content validity evaluation of the Living Beyond Lymphoma survey.

Methods

The development process involved a literature review; this identified the most psychometrical robust and appropriate instruments, which were assimilated into a useable form. Experts (n = 8) with lived experience or clinical expertise in lymphoma assessed the survey's clarity, relevance, and representativeness. Experts made suggestions, such as the addition or deletion of items. Content validity indices were calculated at the item level (I-CVI) and the scale level (S-CVI).

Results

The experts rated the living beyond lymphoma survey as clear (S-CVI/Ave = 0.94 excellent), relevant (S-CVI/Ave = 0.96 excellent) and representative (S-CVI/Ave = 0.94 excellent). Universal agreement for the scale (S-CVI/UA) was lower (range S-CVI-UA = 0.58 – 0.75 fair-good). There was strong evidence supporting the content validity of the living beyond lymphoma survey, providing a valid and comprehensive instrument for use in the assessment of lymphoma cancer survivors’ unmet needs and quality of life outcomes.

Conclusions

Given the excellent average scale agreement but fair to good universal agreement for the scale, the wide variation in experts’ backgrounds and experiences could inadvertently reduce control over item agreement. The instrument was considered helpful for assessing the needs and well-being of lymphoma cancer survivors.

Legal entity responsible for the study

The authors.

Funding

Trinity College Dublin.

Disclosure

A. Drury: Financial Interests, Personal, Full or part-time Employment: University College Dublin; Financial Interests, Institutional, Research Grant, I am a collaborator on the Pfizer-funded project ABC4Nurses, which is coordinated and managed by EONS: Pfizer; Non-Financial Interests, Invited Speaker: European Oncology Nursing Society; Non-Financial Interests, Advisory Role, I am an advisor on several EONS projects, including ABC4Nurses and RCC & HCC PROMS: European Oncology Nursing Society. All other authors have declared no conflicts of interest.

Collapse
EONS session

Q&A and discussion

Lecture Time
17:35 - 17:45
Location
7.3.S - Strasbourg Auditorium, Paris Expo Porte de Versailles, Paris, France
Date
Sat, 10.09.2022
Time
16:45 - 17:45